Cargando…
Augmentation of Creatine in the Heart
Creatine is a principle component of the creatine kinase (CK) phosphagen system common to all vertebrates. It is found in excitable cells, such as cardiomyocytes, where it plays an important role in the buffering and transport of chemical energy to ensure that supply meets the dynamic demands of the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634222/ https://www.ncbi.nlm.nih.gov/pubmed/26202199 http://dx.doi.org/10.2174/1389557515666150722102151 |
_version_ | 1782399316824948736 |
---|---|
author | Zervou, Sevasti Whittington, Hannah J. Russell, Angela J. Lygate, Craig A. |
author_facet | Zervou, Sevasti Whittington, Hannah J. Russell, Angela J. Lygate, Craig A. |
author_sort | Zervou, Sevasti |
collection | PubMed |
description | Creatine is a principle component of the creatine kinase (CK) phosphagen system common to all vertebrates. It is found in excitable cells, such as cardiomyocytes, where it plays an important role in the buffering and transport of chemical energy to ensure that supply meets the dynamic demands of the heart. Multiple components of the CK system, including intracellular creatine levels, are reduced in heart failure, while ischaemia and hypoxia represent acute crises of energy provision. Elevation of myocardial creatine levels has therefore been suggested as potentially beneficial, however, achieving this goal is not trivial. This mini-review outlines the evidence in support of creatine elevation and critically examines the pharmacological approaches that are currently available. In particular, dietary creatine-supplementation does not sufficiently elevate creatine levels in the heart due to subsequent down-regulation of the plasma membrane creatine transporter (CrT). Attempts to increase passive diffusion and bypass the CrT, e.g. via creatine esters, have yet to be tested in the heart. However, studies in mice with genetic overexpression of the CrT demonstrate proof-of-principle that elevated creatine protects the heart from ischaemia-reperfusion injury. This suggests activation of the CrT as a major unmet pharmacological target. However, translation of this finding to the clinic will require a greater understanding of CrT regulation in health and disease and the development of small molecule activators. |
format | Online Article Text |
id | pubmed-4634222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-46342222015-11-05 Augmentation of Creatine in the Heart Zervou, Sevasti Whittington, Hannah J. Russell, Angela J. Lygate, Craig A. Mini Rev Med Chem Article Creatine is a principle component of the creatine kinase (CK) phosphagen system common to all vertebrates. It is found in excitable cells, such as cardiomyocytes, where it plays an important role in the buffering and transport of chemical energy to ensure that supply meets the dynamic demands of the heart. Multiple components of the CK system, including intracellular creatine levels, are reduced in heart failure, while ischaemia and hypoxia represent acute crises of energy provision. Elevation of myocardial creatine levels has therefore been suggested as potentially beneficial, however, achieving this goal is not trivial. This mini-review outlines the evidence in support of creatine elevation and critically examines the pharmacological approaches that are currently available. In particular, dietary creatine-supplementation does not sufficiently elevate creatine levels in the heart due to subsequent down-regulation of the plasma membrane creatine transporter (CrT). Attempts to increase passive diffusion and bypass the CrT, e.g. via creatine esters, have yet to be tested in the heart. However, studies in mice with genetic overexpression of the CrT demonstrate proof-of-principle that elevated creatine protects the heart from ischaemia-reperfusion injury. This suggests activation of the CrT as a major unmet pharmacological target. However, translation of this finding to the clinic will require a greater understanding of CrT regulation in health and disease and the development of small molecule activators. Bentham Science Publishers 2016-01 2016-01 /pmc/articles/PMC4634222/ /pubmed/26202199 http://dx.doi.org/10.2174/1389557515666150722102151 Text en © 2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Zervou, Sevasti Whittington, Hannah J. Russell, Angela J. Lygate, Craig A. Augmentation of Creatine in the Heart |
title | Augmentation of Creatine in the Heart |
title_full | Augmentation of Creatine in the Heart |
title_fullStr | Augmentation of Creatine in the Heart |
title_full_unstemmed | Augmentation of Creatine in the Heart |
title_short | Augmentation of Creatine in the Heart |
title_sort | augmentation of creatine in the heart |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634222/ https://www.ncbi.nlm.nih.gov/pubmed/26202199 http://dx.doi.org/10.2174/1389557515666150722102151 |
work_keys_str_mv | AT zervousevasti augmentationofcreatineintheheart AT whittingtonhannahj augmentationofcreatineintheheart AT russellangelaj augmentationofcreatineintheheart AT lygatecraiga augmentationofcreatineintheheart |